Grants for Public and State controlled institutions of higher education - Federal

This grant provides funding for researchers to conduct multi-site clinical trials focused on effective treatments and preventive interventions for health issues related to aging, specifically targeting older adults with complex health conditions.

This grant provides funding to nonprofit organizations, local governments, and tribal communities in the U.S. to support innovative arts projects that engage the public and strengthen community connections.

This funding opportunity provides financial support for organizations to develop and implement innovative strategies for tuberculosis prevention and detection in high-burden countries, focusing on treatment optimization and improved case finding.

This grant provides funding for research and development projects focused on advancing air superiority technologies, targeting educational institutions, non-profit organizations, and private industry involved in armament technology.

With this solicitation, BJA seeks to support law enforcement, correctional officers, probation and parole, and sheriffs departments in effectively partnering with mental health, substance use, community service professionals and agencies to promote public safety and make sure that appropriate responses are provided to individuals in crisis who have behavioral health conditions, intellectual disabilities, developmental disabilities, or physical disabilities, and/or traumatic brain injuries. Funding Categories: Category 1: Training Program for Law Enforcement Officers, including campus-based police; law enforcement agencies, including probation and parole (field-based); and sheriff's departments (patrol-based) Category 2: Training Program for Correctional Officers, Probation and Parole (facility-based), and Sheriff Departments (facility-based)

With this solicitation OJJDP seeks to provide funding for the development and implementation of comprehensive and culturally relevant training and technical assistance designed to support Tribal efforts to create, enhance, and/or sustain programs, services, and supports for youth in Tribal communities.

The CHIPS Research and Development Program (CHIPS R) aims to advance the development of semiconductor technologies and to enhance the competitiveness of the U.S. semiconductor industry. This is the first Notice of Funding Opportunity under this program. It seeks applications for new research and development (R) activities to establish and accelerate domestic capacity for advanced packaging substrates and substrate materials, a key technology for producing microelectronics systems. This NOFO seeks applications for research and development activities that will establish and accelerate domestic capacity for advanced packaging substrates and substrate materials. Through this NOFO, the NAPMP program seeks to achieve the following objectives: (1) Accelerate domestic R&D and innovation in advanced packaging materials and substrates; (2) Translate domestic materials and substrate innovation into U.S. manufacturing, such that these technologies are available to U.S. manufacturers and customers, including to significantly benefit U.S. economic and national security; (3) Support the establishment of a robust, sustainable, domestic capacity for advanced packaging materials and substrate R&D, prototyping, commercialization, and manufacturing; and (4) Promote a skilled and diverse pipeline of workers for a sustainable domestic advanced packaging industry. NAPMP plans to release subsequent NOFOs relevant to other research areas and for an Advanced Packaging Piloting Facility (APPF), where successful development efforts will be transitioned and validated for scaled transition to U.S. manufacturing. The APPF is expected to be a key facility for technology transfer to high-volume manufacturing.

Funding Opportunity Title: Development and Deployment of Innovative Technologies for Concrete PavementsAnnouncement Type: This is the initial announcement of this funding opportunity.Funding Opportunity Number: 693JJ324NF00013Total Amount Available: This NOFO will result in the distribution of up to $5 million. The actual amount available to be awarded under this notice will besubject to the availability of funds. This NOFO will result in the award of one cost reimbursement cooperative agreement withcost-sharing. Award Type: Cooperative AgreementAssistance Listing Number: 20.200, Highway Research Development Questions: Submit Questions by 3:00pm ET on 4/17/2024 to: [email protected] and [email protected] Application Due Date: Applications Due by 3:00pm ET on 5/20/2024 via Grants.gov (see Section D). The Federal Highway Administrations (FHWA) Accelerated Implementation and Deployment of Pavement Technologies (AIDPT) Program was established more than a decade ago under the Moving Ahead for Progress in 21st Century Act (Pub. L. 112-141). Since that time, the program has continued under Fixing Americas Surface Transportation Act (Pub. L. 114-94) and the Bipartisan Infrastructure Law (Pub. L. 117-58). The program encourages highway agencies to adopt and implement new technologies proven to save money, enhance safety, improve performance and quality, increase efficiency, reduce delay, and enhance road user satisfaction.The purpose of this funding opportunity and planned cooperative agreement (Agreement) is to stimulate, facilitate, and expedite the deployment and rapid adoption of new and innovative technologies relating to the design, specification, production, testing, control, construction, investigation, operation, and impacts of concrete pavements. The Agreement will support public agencies by helping to increase the knowledge related to concrete pavements and concrete materials. The proposed project is a cooperative effort between the FHWA and the Recipient to improve the quality and performance of concrete pavements. Products will include, but not be limited to, implementation plans, market analyses, training tools, case studies, reports and analyses, and supporting stakeholder engagement via conference presentations, webinars, workshops, peer exchanges, videos, and technical assistance to public agencies. To accomplish and deliver these products, it is anticipated the Recipient will leverage engaging subject matter experts and make products available and accessible to a wide-ranging audience. This effort will leverage the unique technology capabilities and facilities of the Recipient with FHWAs mission.The goals of this funding opportunity and planned Agreement are to promote the deployment and rapid adoption of new and innovative materials, design and construction procedures, specifications, practices, and methods by which the concrete pavement can realize improved pavement performance and extended pavement life while integrating sustainability.

HUD is funding studies to improve knowledge of housing-related health and safety hazards and to improve or develop new hazard assessment and control methods, with a focus on lead and other key residential health and safety hazards. HUD is especially interested in applications that will advance our knowledge of priority healthy homes issues by addressing important gaps in science related to the accurate and efficient identification of hazards and the implementation of cost-effective hazard mitigation. This includes studies using implementation sciences in identifying specific conditions under which residential environmental hazard interventions, that have been shown to be effective in specific housing types and residential settings, can be assessed in other contexts.

This funding opportunity provides financial support to early-career researchers from diverse backgrounds to develop innovative cancer research projects and enhance workforce diversity in the field.

The Spotlight on Humanities in Higher Education program, run by the NEH Division of Education Programs, provides funding for small projects that enhance humanities education at smaller colleges and universities, particularly those serving underserved populations, with a focus on community colleges, minority-serving institutions, rural schools, and institutions where over 40% of students receive Pell grants.

The National Institute on Aging (NIA), part of the National Institutes of Health (NIH), intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose to establish a national Open Measurement Coordinating Network for Non-Pharmacological Alzheimer's Disease (AD) and AD-related Dementias (ADRD) Primary Prevention Trials. The Network will serve as a centralized hub for developing, validating, standardizing, and disseminating measures and measurement methods for AD/ADRD primary prevention trials. It will incorporate measures and measurement methods across neuropsychological, biomarker, and functional domains to meet the goal of primary prevention of AD/ADRD centered around brain health equity. Brain health equity is the fair distribution of brain health determinants, outcomes, and resources within and between segments of the population, regardless of social standing. Measures and methods of interest will test outcomes and mechanisms of action in settings customized for individuals with different needs and linked to real-world function. Applications must explain how the platform will meet evolving community needs and partner with other NIA-funded programs. Applications must also describe activities that will achieve the following objectives: Develop an organizational and governance structure to support the administration, innovation, and dissemination functions of the Network. Propose activities to establish a framework that will facilitate the development of innovative strategies for standardization and use of methods and measures across NIA-supported projects and support activities for the discovery and development of innovative and novel measures and data. Disseminate Network resources and products to the broader AD/ADRD research community. Ensure that all measures and methods development and validation occurs in a racially, ethnically, geographically, and diagnostically diverse set of participants, including members of NIH-defined Health Disparity Populations. This also includes establishing the acceptability and feasibility of using the proposed instruments in both cognitively normal individuals and persons living with cognitive impairment (PLWCI), including subjective cognitive decline. NIA is particularly interested in proposals that advance equity for populations disproportionately impacted by AD/ADRD. For example, Black and Hispanic Americans have a higher prevalence of AD/ADRD compared to non-Hispanic White Americans. Resources, including measurement instruments, methods, algorithms, code, documentation, and normative data will enable other, future measures and methods development projects that support AD/ADRD primary prevention research needs. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in early 2024 with an expected application due date in Spring/Summer 2024. This NOFO will utilize the U24 activity code.

This grant provides funding and technical assistance to organizations that help state, local, and Tribal governments improve their planning and permitting processes for large-scale renewable energy projects.

The U.S. Embassy Kigali Public Diplomacy Section (PD) of the U.S. Department of State is pleased to announce that funding is available through its Public Diplomacy Small Grants Program. This is an Annual Program Statement, outlining our funding priorities, the strategic themes we focus on, and the procedures for submitting requests for funding. Please carefully follow all instructions below.Purpose of Small Grants: We invite proposals for programs that strengthen cultural ties between the U.S. and Rwanda through cultural and exchange programming that highlights shared values and promotes bilateral cooperation. All programs must include an American cultural element, or connection with American expert/s, organization/s, or institution/s in a specific field that will promote increased understanding of U.S. policy and perspectives.Examples of PD Small Grants Program programs include, but are not limited to: Academic and professional lectures, seminars and speaker programs; Artistic and cultural workshops, joint performances and exhibitions; Cultural heritage conservation and preservation programs; Professional and academic exchanges and programs;

This funding opportunity supports researchers in developing innovative strategies to target and eliminate HIV-infected cells by studying the HIV envelope protein's expression and its interactions with the immune system.

The NICHD Small Research Grant Program (R03 Clinical Trial Required) supports clinical trials that fall within the NICHD mission. The R03 activity code supports small research projects that can be carried out in a short period of time with limited resources. The R03 program may be used for different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

This funding opportunity supports research projects aimed at improving cancer care and outcomes for sexual and gender minority survivors by addressing healthcare disparities and enhancing access to quality treatment.

This funding opportunity provides financial support for organizations to evaluate and implement overdose prevention strategies targeting communities disproportionately affected by substance use disorders and overdose deaths.

Orthopaedic injuries have a profound impact on military readiness and return to work/activity/duty. In the military, extremity battle wounds comprise approximately 50% of injuries reported in the Department of Defense Trauma Registry. Additionally, orthopaedic injuries and conditions that occur outside of combat (e.g., during training, leisure activities, resultant from old injuries) present one of the greatest threats to the readiness of our Service Members and military. Early stabilization, treatment, and rehabilitation of orthopaedic injuries in both civilian and military populations have led to better outcomes, particularly in the prevention of secondary complications and in minimizing morbidity. Availability of orthopaedic care and treatment as early as possible, or as close to the point of injury as possible, also minimizes limb loss and affects military readiness.Although the PRORP is interested in supporting military-focused research, research supported by the PRORP is expected to also apply to all individuals who have sustained a major orthopaedic injury.With the initiation of the Arthritis Research Program, the FY24 PRORP may not fund arthritis research; however, research that addresses conditions or health abnormalities related to arthritis is permitted provided the proposed research addresses the selected Focus Area.The PRORP CTA supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of military combat or service-related orthopaedic injuries that significantly impact unit readiness and return-to-duty/work rates. Applicants are encouraged to address how the proposed research will support patient care closer to the point of injury and/or allow patients to more quickly return to duty/work. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.The FY24 PRORP CTA differs from the FY24 PRORP Clinical Translational Research Award (CTRA) in that the CTRA allows for clinical research projects that may or may not include a clinical trial, whereas the CTA is restricted to clinical trials only.Funding from this award mechanism must support a clinical trial and may not be used for animal or preclinical studies. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.All applications submitted to this program announcement, regardless of the selected Focus Area, are eligible for Research Level 1.Collaborative Care Option (Research Level 2): Applications submitted to the FY24 PRORP CTA, with Focus Area Translation of Early Findings Soft Tissue Trauma, are eligible for a Collaborative Care Option (Research Level 2); refer to Section II.D.5, Funding Restrictions. The Collaborative Care Option provides additional support to encourage collaborative interdisciplinary research among physical therapists, occupational therapists, prosthetists, surgeons, and other orthopaedic care providers. The proposed research should include both surgical and rehabilitation strategies that create a cohesive project. Surgical strategies are reconstruction and repair and/or application of biologics, pharmaceuticals, and devices for the purpose of restoration of native architecture, composition, and function of traumatically injured tissues. Rehabilitative strategies are those that restore function following injury or illness, with the goal of optimal health and independence. Projects should integrate principles and approaches from surgical and rehabilitative strategies, beyond what each approach would provide by itself, with the goal of optimizing form, function, and independence for those who have sustained traumatic orthopaedic injuries. The rehabilitation strategy and the standard of care must be specified. Projects that follow patients across the continuum of care are highly encouraged. To encourage meaningful and productive multidisciplinary collaborations, projects submitted for this option must include at least one investigator with orthopaedic rehabilitation expertise and at least one clinician who specializes in orthopaedic or trauma care. A Letter of Collaboration is required from each specialist (i.e., rehabilitation expert and surgeon) who is serving as Key Personnel, excluding the Principal Investigator (PI), on the application. A clinician is defined as an individual who is credentialed (possesses the necessary degrees, licenses, and other certifications) and practicing as a care provider in a relevant capacity.If the proposed research includes a clinical trial of an investigational product to be conducted at international sites, an application to the relevant national Regulatory Agency of each host country must be submitted within 6 months of the award date.The government reserves the right to withdraw funding if an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application and/or international regulatory application is necessary but has not been submitted within 6 months of the award date.For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document_DEC2022.pdf.Key aspects of the PRORP CTA mechanism: Clinical Trial Start Date: The proposed clinical trial is expected to begin no later than 6 months after the award date, or 12 months after the award date for studies regulated by the Regulatory Agency. Preliminary Data Are Required: Inclusion of preliminary data relevant to the proposed clinical trial is required. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Intervention Availability: The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study. Personnel and Environment: The application should demonstrate the study teams expertise and experience in all aspects of conducting clinical trials, including appropriate statistical analysis, knowledge of U.S. Food and Drug Administration (FDA) processes (if applicable), and data management. The application should include a study coordinator(s) who will guide the clinical protocol through the local IRB of record and other federal agency regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual. The application should show strong institutional support and, if applicable, a commitment to serve as the FDA regulatory sponsor, ensuring all sponsor responsibilities described in 21 CFR 312, Subpart D, are fulfilled. Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan, a power analysis reflecting sample size projections that will answer the objectives of the study, and a data management plan that includes use of an appropriate database to safeguard and maintain the integrity of the data. If required by a Regulatory Agency, the trial must use a 21 CFR 11-compliant database and appropriate data standards.Womens Health Research: The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health.Use of DOD or VA Resources: If the proposed research involves access to DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.For the purposes of this funding opportunity, Regulatory Agency refers to the FDA or any relevant international Regulatory Agency unless otherwise noted.If the proposed clinical trial involves the use of a drug that has not been approved by the relevant Regulatory Agency for the country where the research will be conducted, then submission of an IND application, or equivalent, that meets all requirements under 21 CFR 312 may be required. It is the responsibility of the applicant to provide evidence from the IRB of record or the relevant Regulatory Agency if an IND, or equivalent, is not required. If an IND, or equivalent, is required, the regulatory application must be submitted to the relevant Regulatory Agency within 6 months of the CTA award start date. The IND, or equivalent, should be specific for the product and indication to be tested in the proposed clinical trial. For more information on IND applications specifically, the FDA has provided guidance at https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application.If the investigational product is a device, then submission of an IDE, or equivalent, application that meets all requirements under 21 CFR 812 may be required. It is the responsibility of the applicant to provide evidence if an IDE, or equivalent, is not required. If an IDE, or equivalent, is required, the IDE application, or equivalent, must be submitted to the relevant Regulatory Agency within 6 months of the CTA award start date. The IDE, or equivalent, should be specific for the device and indication to be tested in the proposed clinical trial.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 PRORP CTA should not exceed $2.5M (Research Level 1) or $3.25M (Research Level 2). Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $13.25M to fund approximately four Research Level 1 and one Research Level 2 CTA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity provides financial support for educational institutions, nonprofit organizations, and government entities to develop public programming and outreach initiatives that commemorate the historic Brown v. Board of Education Supreme Court decision and promote civil rights education across multiple significant locations.